Abstract
T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) inhibitor plus an anti-programmed cell death protein 1 (PD-1) antibody is a promising combination and shows potent efficacy in non-small cell lung cancer (NSCLC). Ociperlimab is a humanized IgG1 monoclonal antibody (mAb) designed to bind to Fc-intact TIGIT with high affinity and specificity. Tislelizumab is an anti-PD-1 mAb approved for the treatment of NSCLC in China. AdvanTIG-105 is a Phase 1/1b open-label study designed to assess the safety and preliminary antitumor activity of ociperlimab plus tislelizumab in patients with advanced, metastatic unresectable solid tumors (NCT04047862).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
